John Johnston, a director at MaxCyte, Inc. (NASDAQ:MXCT), a $434 million market cap company, recently sold 3,000 shares of common stock, generating $12,020. The shares were sold at a weighted average price of $4.007 per share, with individual transaction prices ranging from $3.995 to $4.06, near the lower end of its 52-week range of $3.17-$5.54. These transactions were executed under a Rule 10b5-1 trading plan that Johnston adopted on December 19, 2023.
In addition to the sale, Johnston exercised options to acquire 3,000 shares of MaxCyte common stock at a price of $2.932 per share. Following these transactions, Johnston holds 141,950 shares directly.
The option exercise and subsequent sale were part of planned transactions, as indicated by the trading plan, ensuring transparency and compliance with SEC regulations.
In other recent news, MaxCyte, Inc. disclosed its financial results for the third quarter ending September 30, 2024. The earnings call, led by President and CEO Maher Masoud, and CFO Doug Swirsky, provided insights into the company's performance and future strategies. The leadership team expressed optimism about MaxCyte's trajectory and future performance, despite acknowledging potential factors that could cause actual results to differ from projections. Forward-looking statements were made, underlining the inherent uncertainty of such predictions. No specific financial misses were discussed during the call. The executives' discussions and the subsequent Q&A session offered stakeholders a clearer understanding of MaxCyte's strategic direction and operational focus. These are among the recent developments in the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.